Neurotech International Ltd has released a press release.
20 Week Data Shows Significant Improvement For ASD Children
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
In the deck
Story so far
Earlier from Neurotech International
- New Phase I/II Clinical Trial in Children with PANDAS/PANS
- Executive Change
- Q&A on NTI164 Breakthrough Clinical Trial Results in ASD
- Reinstatement to Official Quotation
- Breakthrough results with NTI164 in paediatric asd
Later from Neurotech International
- Suspension From Official Quotation
- Neurotech Completes $9.0M Placement
- Reinstatement to Quotation
- Neurotech Receives $1.2M R&D Tax Rebate
- NTI Receives HREC/TGA Approval for Phase II/III ASD Trial
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International